Although Vertex (NASDAQ:VRTX) is still up 20% for the year as a whole, it dropped by about a fifth of its share price in November. The stock has been hit twofold. Results keep pouring in from both Abbott Labs' (NYSE:ABT) and Gilead's (NASDAQ:GILD) next generation hepatitis-C drug cocktails, with tremendous cure rates and without requiring the use of interferon -- you start to see the problem for Vertex's Incivek. Furthermore, quarterly results had sales of its cystic fibrosis drug coming in light of estimates, but international expansion should accelerate its growth. Watch and find out what David Williamson thinks about Vertex's month and what the future holds for the stock.
